WebMD21h
New FDA Warning Added to Popular Weight Loss Drugs
Nov. 6, 2024 – The FDA has updated the labels for all GLP-1 weight loss drugs with a warning about pulmonary aspiration ...
Novo Nordisk expects high demand for its obesity drugs in India, says country head
Popular weight-loss drug Wegovy maker Novo Nordisk expects high demand and acceptance for its anti-obesity drug, when ...
Nature2d
How ‘miracle’ weight-loss drugs will change the world
These are just some of the ways in which analysts forecast that the new wave of incredibly effective weight-loss drugs, known ...
Is Eli Lilly and Company (LLY) the Best Pharma Stock to Buy Right Now?
We recently compiled a list of the 10 Best Pharma Stocks To Buy Right Now. In this article, we are going to take a look at ...
10 Best Pharma Stocks To Buy Right Now
In this article, we will take a look at the 10 Best Pharma Stocks To Buy Right Now.
As Race To Best 'Miracle' Obesity Drug Heats Up, Ozempic Maker Novo Nordisk Tests New Hybrid Drug That Can Reduce Weight Up To 25%
Novo Nordisk A/S (NYSE:NVO) is advancing its research on a pioneering hybrid drug, CagriSema. This drug merges semaglutide ...
Novo’s New Obesity Drug Is Targeting the Most Dramatic Weight Loss Yet
The drugmaker hopes to show CagriSema leads to at least 25% weight loss, without increased side effects. Its lead in a ...
Kelly Osbourne turns 40 with dramatic transformation after weight, addiction battles
Kelly Osbourne stunned in photos from her 40th birthday party, looking happy after decades of body image and addiction issues ...
Futurism5d
Eli Lilly Has a Major Problem With Its Weight Loss Drugs Zepbound and Mounjaro
Eli Lilly, the maker of the popular weight loss drug Zepbound, revealed a "shocking first miss" during its most recent ...
Hoping for a weight-loss pill? It could get closer to reality next week.
The company is expected to offer data on the higher dosing arms of 60, 80 and 100 milligrams at Obesity Week, which is organized by the Obesity Society and takes place Nov. 3-6 in San Antonio, Texas.
Novo's trial of weight-loss drug shows improvement in fatty liver disease
Novo Nordisk said on Friday its weight-loss drug Wegovy met the main goal of a late-stage trial by showing improvement in liver fibrosis with no worsening of steatohepatitis.